60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report)‘s stock had its “neutral” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports.
60 Degrees Pharmaceuticals Stock Performance
Shares of SXTP traded up $0.40 during trading hours on Wednesday, hitting $2.35. The stock had a trading volume of 2,767,188 shares, compared to its average volume of 277,863. The firm has a 50-day moving average price of $1.01 and a 200 day moving average price of $0.83. 60 Degrees Pharmaceuticals has a fifty-two week low of $0.70 and a fifty-two week high of $18.36. The firm has a market capitalization of $5.40 million, a price-to-earnings ratio of -0.23 and a beta of 5.36.
Insider Activity at 60 Degrees Pharmaceuticals
In other news, CEO Geoffrey S. Dow bought 35,823 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was purchased at an average cost of $1.27 per share, for a total transaction of $45,495.21. Following the purchase, the chief executive officer now directly owns 94,580 shares in the company, valued at approximately $120,116.60. This trade represents a 60.97 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders bought a total of 59,372 shares of company stock worth $70,410 in the last three months. Company insiders own 10.27% of the company’s stock.
60 Degrees Pharmaceuticals Company Profile
60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.
See Also
- Five stocks we like better than 60 Degrees Pharmaceuticals
- Differences Between Momentum Investing and Long Term Investing
- The Great CPU Race: AMD and Intel Battle for Dominance
- What Makes a Stock a Good Dividend Stock?
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- How to Use High Beta Stocks to Maximize Your Investing Profits
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
